Clinical Trial Update: Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immunogenicity and safety of an inactivated COVID-19 vaccine in patients aged 60 and older with chronic bronchitis and COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchitis
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• inactivated COVID-19 vaccine

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: COVID-19, Chronic Bronchitis | Phase 4 | Status: UNKNOWN